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Background: Water-soluble fullerenes have recently 
been shown to exhibit considerable in vitro biological 
activity including cytotoxicity, site-selective DNA cleav- 
age and inhibition of HIV protease. To assess the poten- 
tial of these compounds as drugs, studies on the in oiuo 
behavior of fullerenes are needed. We therefore set out to 
synthesize a radiolabeled, water-soluble fuIIerene, in 
order to obtain data on the oral absorption, distribution 
and excretion of this class of compounds. 
Results: We synthesized a 14C-labeled water-soluble 
[60]fuIIerene using dipolar trimethylenemethane, which 
undergoes cycloaddition to [60]fXIerene.When adrninis- 
tered orally to rats, this compound was not efficiently 
absorbed and was excreted primarily in the feces. When 
injected intravenously, however, it was distributed rapidly 
to various tissues, and most of the material was retained in 
the body after one week.The compound was also able to 
penetrate the blood-brain barrier. Acute toxicity of the 
water-miscible lllerene was found to be quite low. 
Conclusions: Although the water-soluble fuIIerenes (and 
possibly their simple metabolites) are not acutely toxic, 
they are retained in the body for long periods, raising con- 
terns about chronic toxic effects.The fact that fullerenes 
distribute rapidly to many tissues suggests that they may 
eventually be useful to deliver highly polar drugs through 
membranes to a target tissue, however, and they may even 
have applications in the delivery of drugs to the brain. 
Recent advances in fnllerene synthetic chemistry may also 
make it possible to control fnllerene absorption/excretion 
profiles in the future. 
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Introduction 
Despite intense interest in the fullerene molecule ever 
since its discovery, fullerene biology has only become a 
realistic target of scient:ific research since the recent 
demonstration that water-soluble fullerenes (for 
example, compounds 1 and 2 in Fig. 1) show consider- 
able in vitro biological activity, including cytotoxicity, 
DNA cleavage [l] and anti-viral activity [2,3]. We 
recently showed that a C&,-DNA conjugate could be 
used to cleave single- and double-stranded DNA at spe- 
cific sites [4], further demonstrating that tailor-made 
fullerenes could be useful in biochemical and biological 
studies. Current studies on the in viva behavior of 
fullerenes are expected to provide fundamental infor- 
mation for the further development of fullerene 
biology, and eventually to bring forth new drug delivery 
systems for diagnosis and therapy. Here, we report the 
first data, to our knowledge, on the oral absorption, dis- 
tribution and excretion of a water-miscible fullerene. 
These studies required the synthesis of the radioactive 
compound la (see Fig. I). 
The fullerene la was not effectively absorbed when 
administered orally (p.0.). Nonetheless, a small amount 
was absorbed, metabolized and excreted into the urine. 
When injected intravenously (i.v.), most of the radio- 
labeled compound moved rapidly to the liver and was 
then distributed to various other tissues. Thus it seems 
that, despite its chemical reactivity [5], the fullerene does 
not become quickly bound to reactive substances, such 
as the amine residues of proteins (for example, lysine 
and ornithine). Excretion was slow, however, and over 
90 % was still retained in the body after one week.Thus, 
the chronic toxicity of water-miscible fullerenes will be 
an important focus of future work. 
Results and discussion 
We first investigated the acute toxicity of the water- 
soluble fullerene 2. The studies were performed on 
mice (ddY female, 18-20 g) by a single intraperitoneal 
(i.p.) injection (200-500 mg kg-l doses, in 0.2 % 
Tween 80LSaline containing dimethylsulfoxide). 
Although the mice showed symptoms of discomfort 
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Fig. 1. Synthesis of the 14C-labeled 
fullerene la. For conditions used, see 
Materials and methods. 
after dosing, such as writhing with stretching of the 
trunk, and some weight loss (5-10 % weight loss after a 
day at a dose of 500 mg kg-’ of compound 2), all mice 
survived for a period of one week.As the approximate 
lethal dose must thus be more than 500 mg kg-’ i.p., 
and given similar data for the parent C,, [6-81, 
fullerenes may be regarded as compounds with rela- 
tively weak acute toxicity provided that they are 
manipulated with reasonable care. A full evaluation of 
the toxicity of these compounds awaits further studies. 
To address basic issues of the pharmacokinetics and dis- 
tribution of these compounds, a synthetically viable 
route to a labeled fullerene derivative was needed. Of 
the two possible strategies for making labeled 
fullerenes, the simplest conceptually is the labeling of 
the C,, core carbons with 14C. This route, however, is 
difficult to perform practically [7,8]. It involves a 
several-step synthesis of 14C-enriched graphite, and 
requires the handling of a large amount of radioactive 
soot, from which the labeled C,; is separated. The 
second route, involving attachment of a labeled carbon 
fragment to the fullerene, may be far less hazardous, 
more isotopically economic, and may also be applicable 
to fullerenes other than C,,. 
Among the reported methods for fullerene functional- 
ization, the trimethylenemethane (TMM) route [9,10] 
appeared to be ideal for rendering the second labeling 
strategy practicaLThe synthesis of labeled compound la 
was achieved in four synthetic steps (Fig. l).The readily 
available cyclopropenone, compound 3 [ll], was lithi- 
ated and allowed to react with 14CH,I (>97 % isotopic 
purity). The methylated product, compound 4, was iso- 
merized with tert-BuOK to the methylenecyclopropane 
5, and then allowed to react with C,, at 80 ‘C via the 
trimethylenemethane 6.The cycloadduct 7 was purified 
and esterified to obtain the labeled succinate la. The 
mechanism of the TMM reaction, previously studied for 
a 13C-labeled compound [12], ensures that the 14C label 
is placed unambiguously at the position next to the C,, 
core, where the probability of the premature biological 
loss of the label is smallest. 
Absorption of the water-soluble flerene la administered 
orally to male Fischer rats was found to be poor. Only 
trace radioactivity was found in the liver and other tissues 
after 3 and 6 h periods, and virtually all radioactivity 
(97 % of the total) was excreted in the feces within 48 h 
(Fig. 2). It is notable, however, that trace amounts of 
fUerene derivatives were identified in the urine, indicat- 
ing that a small amount of compound la did pass through 
the gastrointestinal wall. In the O-12 h period, a small 
amount of compound la itself was tentatively detected 
(using HPLC) in the urine, and, in the 24-30 h period, 
trace amounts of la and 7a were detected after acidifica- 
tion of the urine. In the 24-30 h sample, we could not 
initially detect any CH$&-soluble radioactive material in 
the urine sample @H 8), but found, upon acidification to 
pH 1 with HCl, that one third of the radioactivity did 
move to the CH,Cl, extract.Two radioactive zones were 
separated by HPLC (Buckyprep column, CH,Cl,). The 
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When the dose was delivered intravenously (i.v.), com- 
pound la was excreted extremely slowly (Fig. 2). After 
160 h, only 5.4 % was eliminated into the feces and the 
remainder stayed in the body, In both p.o. and i.v. experi- 
ments, virtually all of the excretion occurred via the 
feces, and little radioactivity was seen in the urine. The 
strong retention of the i.v.-dosed fullerenes is consistent 
L 
with the high lipophilicity of the molecule. Compound 
1 is unusually lipophilic for a carboxylic acid derivative, 
as evidenced by its high log P, value (the partition 
coefficient in octanol/water [13]) of 4.5 (free acid form), 
which is in the same range as that of phenanthrene (log 
12 30 36 42 48 72 Pow = 4.5) and 1,2-diphenylethane (log P,,, = 4.8). 
18 d0 16 12 18 h 46 
Time (h) 
As the i.v.-administered fullerene la is strongly retained 
in the body, we examined the time-dependent change of 
the concentration of the radioactivity in tissues in sacri- 
Fig. 2. Fecal excretion of radioactivity after oral (blue) and ficed animals (Table 1). The dosed fullerene quickly 
intravenous (red) dosing of compound la. passed from the blood to the liver, leaving 1.6 % of the 
: : 
may have been present as the carboxylate salt at pH 8, in 
which case the lack of extraction may simply reflect a lack 
of solubility in the organic solvent used. 
retention times of these compounds were consistent with 
those of compounds 7a and la, as determined by com- 
parison with the retention times of authentic samples (in a 
7.5:1 ratio, giving retention times of 10 and 18 min, 
respectively).The fact that compounds la and 7a could 
be extracted only at pH 1 suggested that, in the urine, 
they existed as acid-labile metabolites, as is often observed 
for lipophilic drugs. It is also possible that compound la 
Table 1. Distribution of radioactivity in rats. 
% total dosed radioactivity 
(concentrations of radioactivity (pg equiv/g)) 
tissue lh 3h 6h 16h 30 h 160h 
liver 72.9 f 13.7 84.7 i 10.4 86.7 f 20.2 91.7 f 8.0 80.1 f 13.4 1.62 zrz 0.31 
(57.7 f 4.8) (57.3 i 8.3) (62.2 f 14.6) (61.9 i 6.3) (54.5 zt 7.6) (0.29 f 0.03) 
spleen 0.74 f 0.63 1.4 f 0.1 1.2 f 0.3 1.6 f 0.2 2.0 f 0.4 0.05 f 0.00 
(11.5 f 2.2) (10.6 i 0.7) (8.7 f 2.1) (11.4 f 2.4) (12.4 * 1 .O) (0.12 f 0.01) 
lungs 1.4 1 0.3 5.0 f 3.3 1.4 f 0.3 1 .o f 0.3 3.2 zt 2.3 0.05 f 0.02 
(5.5 * 0.7) (22.9 f 13.5) (5.9 i 1.2) (4.2 f 0.6) (12.7 f 9.2) (0.06 i 0.02) 
kidney 0.50 f 0.04 0.58 zt 0.15 0.99 f 0.18 1 .o f 0.3 3.2 f 0.1 0.41 f 0.14 
(1.3 10.1) (1.5 f 0.2) (2.5 f 0.4) (2.7 f 0.8) (1.8 i 0.2) (0.35 f 0.10) 
heart 0.31 zt 0.25 0.44 f 0.65 0.24 f 0.08 1.07 i 0.16 0.26 zt 0.13 0.01 f 0.00 
(1.8 :t 1.3) (3.7 i 5.7) (1.5 f 0.5) (5.8 f 1.3) (1.5 f 0.8) (0.03 f 0.00) 
brain 0.20 f 0.04 0.15 f 0.24 0.84 f 0.70 0.57 f 0.19 0.10 f 0.11 0.00 f 0.00 
(0.30 i 0.06) (0.24 zt 0.37) (1.2 * 1 .O) (0.85 f 0.24) (0.14 zt 0.16) (0.00 f 0.00) 
testicles 0.03 * 0.00 0.04 f 0.02 0.06 f 0.01 0.09 f 0.01 0.08 zt 0.02 0.07 f 0.01 
(0.12 i 0.01) (0.14 f 0.07) (0.20 * 0.03) (0.26 i 0.02) (0.21 f 0.05) (0.05 f 0.00) 
blood 1.6 f 0.6 1 .o f 0.2 0.50 * 0.12 0.57 i 0.27 0.50 f 0.08 0.00 f 0.00 
(1.6 f 0.3) (0.87 f 0.05) (0.45 f 0.11) (0.45 f 0.20) (0.38 f 0.04) (0.00 f 0.00) 
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total radioactivity in the blood after 1 h and only 0.5 % 
after 6 h. In the liver, 73 % of the radioactivity was found 
after 1 h, and the concentration was maximal after 
6-16 h. About 80 % of the total radioactivity was 
retained in the liver even after 30 h, but the radiolabel 
was mostly eliminated (1.6 %) after 160 h. 
The concentrations of compound la in the spleen and 
kidney were highest after 30 h and accounted for 2-3 % 
of the total radioactivity dosed initially. Notably, the 
radioactivity was also found in the brain. The high 
lipophilicity and the rather compact structure of the 
fullerene la must be responsible for the transportation of 
this large molecule (molecular weight 995) through the 
blood-brain barrier. From 30 to 160 h, the radioactivity 
in the various organs decreased in a time-dependent 
manner and, after 160 h, the radioactivity found in the 
organs listed in Table 1 mostly disappeared without 
excretion from the body, and became distributed to 
skeletal muscle and hair (data not shown). 
Significance 
Fullerenes have attracted considerable interest 
since their first synthesis ten years ago, partly for 
the intrinsic interest of their unusual structure, but 
also because of increasing evidence that they can 
be biologically active themselves, and can be used 
as cages or carriers for other biologically active 
molecules. To determine whether fullerenes will 
ever be useful as drugs or drug delivery devices, it 
is necessary to understand the pharmacokinetics 
and toxicity of these compounds. 
Although we have found that the fullerenes (and 
possibly their simple metabolites) are not acutely 
toxic, they are not free from undesirable effects 
such as pain and weight loss. Our observation that 
the administered fullerene is retained in the body 
for long periods may also raise new concerns 
about chronic toxicity. From a more positive per- 
spective, however, our data suggest that it may in 
the future be possible to use fullerenes to mediate 
the delivery of highly polar drugs attached to the 
fullerene (such as a &,-oligo DNA conjugate 
capable of site-specific DNA cleavage) [1,4] 
through membranes to a target tissue. In addition, 
these studies suggest that water-soluble derivatives 
may enable the delivery of metals into the brain 
in the form of endohedral metallofullerenes [14], 
offering new possibilities for imaging agents. 
Given the recent advances in fullerene synthetic 
chemistry [15-171, it should also soon be possible 
to alter fullerene absorption/excretion profiles. 
Materials and methods 
Synthesis of 74C-labeled fullerene la 
The labeled fullerene was synthesized according to the proce- 
dure previously reported for an unlabeled compound [l], as 
summarized in Fig. 1. Product identification was achieved 
using ‘*C-authentic samples at the stage of both alcohol 7 and 
acid la under two different chromatographic conditions (TLC 
(silica gel, 10 % EtOAc in toluene) and HPLC (Buckyprep 
column, CH,Cl,)). Reagents and conditions were as follows: 
(u) compound 3 (0.15 mmol), n-BuLi (0.15 mmol), hexa- 
methylphosphoric triamide (0.30 mmol), tetrahydrofuran, 
-78 ‘C, 0.5 h, then 14CH,I (0.10 mmol, 0.21 GBq/mmol), 
-78 ‘C + room temperature (r.t.); (b) t-BuOK (0.05 mmol), 
Et20/dimethylsulfoxide, r.t., 1 h; (c) C,, (0.10 mmol), 
1,2-dichlorobenzene, 80 “C, overnight; (d) succinic anhydride 
(1.0 mmol), 4-dimethylaminopiridine (1.0 mmol), CH,Cl,, 
r.t., overnight. Unoptimized yield 0.4 %.The low yield is due 
to inadvertent material loss at stage (a) and the remaining 
transformations took place cleanly, as monitored by chro- 
matography. The optimized yield was 13 % for a sample of 
natural isotopic abundance.The radiolabeled sample contained 
411 % of a faster-moving radioactive impurity as analyzed by 
HPLC (Buckyprep column, Nakalai tesque, Japan, elution 
with 30 % i-PrOH in CH,Cl,). 
Fecal excretion of radioactivity after po. and i.v. dosing of 
compound la 
The excretion of compound la was studied for three male rats 
(Fischer rats; 85-95 g) in each case.The 14C-labeled compound 
la, dissolved in EtOH/PEG400/5 % aqueous albumin (1:1:23, 
0.18 MBq ml-‘), was administrated p.o. (18 l&q) or i.v. 
(9.6 kBq). The radioactivity was measured using a liquid scin- 
tillation counter for samples of the feces, which were treated 
with 1N NaOH at 60 ‘C for 2 days. While the p.o. dosed rats 
excreted 97 % of the total radioactivity after 48 h, only 5.4 % of 
the radioactivity was excreted after 96 h in the i.v. dosed rats. 
Excretion into the urine was also measured using a liquid scin- 
tillation counter. In the p.o. dosing experiment, an initial 
(O-12 h period) urinary excretion of compound la was found 
(taken up in CH,Cl, by extraction), which accounted for 
-0.2 % of the dosed radioactivity.Trace amounts of compounds 
la and 7a were also found in the acidified urine sample of the 
24-30 h period, as described in the text. Compound identifica- 
tion was achieved by comparison of HPLC retention times 
against authentic samples (Buckyprep column, CH,Cl,). 
Distribution of radioactivity in rats 
The distribution of the labeled firllerene la was investigated 
with male rats (Fischer rats; 85-95 g) for the liver, spleen, lungs, 
kidney, heart, brain, testicles and blood. A solution of the 
fullerene la (14 kBq) in a mixture of ethanol (50 p,L), polyethyl- 
ene glycol (50 pL) and 4 % albumin (115 pL) was administered 
by i.v. injection. The distribution in each tissue was analyzed 
after 1,3,6,16,30 and 160 h periods (In the 160 h run, 18 kBq 
of compound la was administered).The rats were dissected after 
the blood was removed with a hypodermic syringe. Each of the 
tissues was homogenized in 2N NaOH at 60 ‘C for 24 h.The 
radioactivity was measured using a liquid scintillation counter. 
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